3D'Aquila RT, Hughes MD, Johnson VA, etal. Nevirapine, zidovudine and didanosine com- pared with zidovudine and didanosine in peti- ents with HIV-1 infection [J]. Ann Intern Med, 1996, 124:1019-1030.
3Carr A, Sarnaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998,12 (7): 51
4Katzenstein D. Adherence as a particular issue with protease inhibitors. J Assoc Nurses AIDS Care, 1997,8(Suppl): 10
5Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors. A review for clinicians. J Am Med Assoc, 1997,277(2): 145
6International Association of Physicians in AIDS care. Scaling up antiretroviral therapy in resource-limited settings:guidelines for a public health approach. IAPAC Mon, 2002,8 (6): 168
7Cheesernan SH,Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial singlerising- dose study in humans. Antimicrob Agents Chemother , 1993,37(2): 178
8Raffi1 F, Reliquet V, Ferrel V, et al. The VIRGO Study: nevirapine, didanosine and stavudine combination therapy in antiretroviralna? ve HIV-1-infected adults. Antiviral Ther,2000,5(4) :267
9Spruance SL, Pavia AT, Mellors JW, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. Ann Intern Med, 1997,126(5) :355
10Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for the Use of Antiretroviral Agents among HIV-Infected Adults and Adolescents.Ann Intern Med ,2002,137(5 Pt 2) :381
